

Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 028622/0102	SERIAL NO. 09/673,735		
INFORMATION DISCLOSURE CITATION  (Use several sheets if necessary)		APPLICANT		FILED 12/21/00			
		Bernd DORKEN et al.		FILING DATE December 27, 2000	GROUP ART UNIT Unassigned		
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
<b>FOREIGN PATENT DOCUMENTS</b>							
REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
						YES	NO
LA	A1 ✓	195 31 348	2/27/97	Fed. Republic of Germany	—	—	X
LA	A2 ✓	0 505 908	9/30/92	Europe	—	—	
LA	A3 ✓	91/09968	7/11/91	WIPO	—	—	
LA	A4 ✓	95/11922	5/4/95	WIPO	—	—	
LA	A5 ✓	96/36360	11/21/96	WIPO	—	—	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
LA	A6 ✓	H. Bohlen et al., "TREATMENT OF EB-VIRUS INDUCED B-CELL LCL IN SCID-HU MICE USING CD3XCD19 BISPECIFIC AND CD28 ANTIBODIES.", Proceedings of the American Association for Cancer Research, vol. 35, March, 1994, pg. 510, XP-002076122, abstract.					
LA	A7 ✓	Jan De Jonge et al., "Bispecific antibody treatment of murine B cell lymphoma.", Cancer Immunology Immunotherapy, vol. 45, No. 3/4, pp. 162-165, XP-002076120, Springer-Verlag, 1997					
LA	A8 ✓	Sergey M. Kipriyanov et al., "BISPECIFIC CD3 X CD19 DIABODY FOR T-CELL-MEDIATED LYSIS OF MALIGNANT HUMAN B CELLS.", International Journal of Cancer, vol. 77, August 31, 1998, pp. 763-772, XP-002115487, Wiley-Liss, Inc., 1998					
LA	A9 ✓	P. Kufer et al., "Construction and biological activity of a recombinant bispecific single-chain antibody designed for therapy of minimal residual colorectal cancer.", Cancer Immunology Immunotherapy, vol. 45, No. 3/4, pp. 193-197, XP-002076121, Springer-Verlag, 1997					
LA	A10 ✓	Anja Schroder et al., "A RECOMBINANT BISPECIFIC SINGLE CHAIN ANTIBODY CD19XCD3 INDUCED RAPID B CELL LYMPHOMA-DIRECTED CYTOTOXICITY OF UNSTIMULATED HUMAN T CELLS.", 40th Annual Meeting Of The American Society Of Hematology Miami Beach, Florida, December 4-8, 1998, XP-002115457, abstract.					
EXAMINER			DATE CONSIDERED 11/20/03				
<p>* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.</p>							

Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 028622/0102	SERIAL NO. 09/673,735	
INFORMATION DISCLOSURE CITATION  (Use several sheets if necessary)		APPLICANT Bernd DORKEN et al.			
		FILING DATE December 27, 2000	GROUP ART UNIT Unassigned		
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
<p style="text-align: center;">14</p> <p style="text-align: center;">15</p> <p style="text-align: center;">16</p>	A11	"National Cancer Institute Sponsored Study of Classifications of Non-Hodgkin's Lymphomas, Summary and Description of a Working Formulation for Clinical Usage.", Cancer, vol. 49, pp. 2112-2135, 1982, (Exhibit 1)			
	A12	Harald Stein et al., "Die neue WHO-Klassifikation der malignen Lymphome.", Deutsches Arzteblatt, vol. 96, pp. C-2302-C-2309, December, 1999, including English language summary, (Exhibit 2)			
	A13	Parveen Kumar et al., 3rd Edition, Clinical Medicine, pp. 369-370, Bailliere Tindall, (Exhibit 3)			
	A14	Jan De Jonge et al., "PRODUCTION AND CHARACTERIZATION OF BISPECIFIC SINGLE-CHAIN ANTIBODY FRAGMENTS.", Molecular Immunology, vol. 32, No. 17/18, pp. 1405-1412, 1995, (Exhibit 4)			
	A15	Jan De Jonge et al., "In Vivo Retargeting of T Cell Effector Function by Recombinant Bispecific Single Chain Fv (Anti-CD3 X Anti-Idiotype) Induces Long-Term Survival in the Murine BCL1 Lymphoma Model1.", The Journal of Immunology, vol. 161, pp. 1454-1461, 1998, (Exhibit 5)			
	A16	Matthias Mack et al., "Biologic Properties of a Bispecific Single-Chain Antibody Directed Against 17-1A (EpCAM) and CD3.", Proceedings of the National Academy of Science, vol. 92, pp. 7021-7025, 1995, (Exhibit 6)			
EXAMINER		DATE CONSIDERED 11/20/03			
<p>* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.</p>					